Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and com ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease ...

(RTTNews) - Daiichi Sankyo (DSKYF.PK) and Merck & Co Inc. (MRK) said that they have reached a global development and commercialization agreement worth up to $22 billion for three of Daiichi Sankyo ...

Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2023, it had a debt/adjusted EBITDA ratio of 0.42 times and over JPY 1.2 trillion in ...

Daiichi Sankyo agreed to pay Ambit shareholders approximately $315 million upfront through a tender offer followed by a merger with a Daiichi Sankyo subsidiary, plus one Contingent Value Right ...

Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22 billion. Merck and Daiichi Sankyo will develop and commercialize ...

AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer.

Daiichi Sankyo and AstraZeneca Joint Executive Committee (JEC) Left to Right: David Fredrickson, Executive Vice President, Global Head Oncology Business Unit, AstraZeneca; José Baselga, MD, PhD ...

AstraZeneca PLC said Monday that it has entered into an oncology collaboration with Daiichi Sankyo Co. worth up to $6 billion that it said could redefine treatment standards in lung, breast and ...

Daiichi Sankyo has agreed to buy Ambit Biosciences for about $315 million, pointing to the potential of Ambit's drug candidate quizartinib, which is in late-stage trials for the treatment of acute ...

About Venture Science Laboratories, Daiichi Sankyo As part of the effort to increase drug discovery research capabilities, VSL was launched in the Daiichi Sankyo R&D Division in April 2013. As an ...